ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO658

Rates of Major Events in Untreated Patients Diagnosed With Anemia of CKD in France

Session Information

  • Anemia and Iron Metabolism
    November 03, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
    Abstract Time: 10:00 AM - 12:00 PM

Category: Anemia and Iron Metabolism

  • 200 Anemia and Iron Metabolism

Authors

  • Requena, Gema, GlaxoSmithKline, Brentford, Middlesex, United Kingdom
  • Stengel, Benedicte, CKD REIN, Paris, France
  • Lambert, Oriane, CKD REIN, Paris, France
  • Massy, Ziad, CKD REIN, Paris, France
  • De Gouville, Anne-Charlotte Monnier, GlaxoSmithKline, Paris, France
  • Wetten, Sally, GlaxoSmithKline, Brentford, Middlesex, United Kingdom
  • Cunnington, Marianne, GlaxoSmithKline, Brentford, Middlesex, United Kingdom
Background

New treatments for anemia of chronic kidney disease (CKD) within the hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) class have recently been approved or are in development. Evidence of background rates of major events of interest in the eligible population will improve the understanding of the benefit/risk of these new products. We describe rates of events of interest among eligible non-dialysis dependent (NDD) patients with anemia of CKD not receiving an erythropoiesis-stimulating agent (ESA).

Methods

CKD-REIN is a prospective cohort study that collected demographic and clinical information from 3033 NDD patients with CKD (stage 3–5 at enrolment) in France. All participants were assessed annually between July 2013–Dec 2019, and outcomes data were limited to fatal and hospitalization events. Anemia was defined by hemoglobin level (<13 g/dl for men, <12 g/dl for women). Patients were followed from the study entry (index date) until the event of interest or censoring for end of the study period, ESA use, dialysis, kidney transplant or death.

Results

1,118 patients had anemia and were ESA-naïve at entry into CKD-REIN. Mean age was 68 yrs and 67% were men. The most common comorbidities were hypertension (97%), hyperlipidemia (67%) and diabetes (50%). The highest event rates of interest were all-cause mortality, heart failure, septicemia and malignancies (Table).

Conclusion

Results indicate that septicemia, heart failure and malignancies were common among these anemic CKD patients. The major complications observed will help physicians to better understand and manage these patients.